Design, Synthesis, and Biological Screening for Cytotoxic Activity of Monastrol Analogues

References

• F. Kurniawan, Y. Miura, R. E. Kartasasmita, A. Mutalib, N. Yoshioka, and D. H. Tjahjono, “In Silico Study, Synthesis, and Cytotoxic Activities of Porphyrin Derivatives,” Pharmaceuticals 11, no. 1 (2018): 8–18.
   Web of Science ®Google Scholar
• G. Charitos, D. T. Trafalis, P. Dalezis, C. Potamitis, V. Sarli, P. Zoumpoulakis, and C. Camoutsis, “Synthesis and Anticancer Activity of Novel 3,6-Disubstituted 1,2,4-Triazolo-[3,4-b]-1,3,4-Thiadiazole Derivatives,” Arabian Journal of Chemistry 12, no. 8 (2019): 4784–94.
   Web of Science ®Google Scholar
• F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 68, no. 6 (2018): 394–424.
   PubMed Web of Science ®Google Scholar
• E. S. Moghadam, F. Saravani, S. Ostad, S. Tavajohi, M. P. Hamedani, and M. Amini, “Design, Synthesis and Cytotoxicity Evaluation of Indibulin Analogs,” Heterocyclic Communications 24, no. 4 (2018): 211–7.
   Web of Science ®Google Scholar
• A. T. A. Borae, P. K. Singh, M. Sechi, and S. Satta, “Discovery of Novel Functionalized 1,2,4-Triazoles as PARP-1 Inhibitors in Breast Cancer: Design, Synthesis and Antitumor Activity Evaluation,” European Journal of Medicinal Chemistry 182 (2019): 111621.
   PubMed Web of Science ®Google Scholar
• M. M. Ghorab, M. S. Alsaid, M. S. Al-Dosary, Y. M. Nissan, and S. M. Attia, “Design, Synthesis and Anticancer Activity of Some Novel Thioureido-Benzenesulfonamides Incorporated Biologically Active Moieties,” Chemistry Central Journal 10, no. 1 (2016): 1–13.
   PubMedGoogle Scholar
• P. Doan, A. Karjalainen, J. G. Chandraseelan, O. Sandberg, O. Yli-Harja, T. Rosholm, R. Franzen, N. R. Candeias, and M. Kandhavelu, “Synthesis and Biological Screening for Cytotoxic Activity of N-Substituted Indolines and Morpholines,” European Journal of Medicinal Chemistry 120 (2016): 296–303.
   PubMed Web of Science ®Google Scholar
• N. Gurrapu, E. P. Kumar, P. K. Kolluri, S. Putta, S. K. Sivan, and N. J. P. Subhashini, “Synthesis, Biological Evaluation and Molecular Docking Studies of Novel 1,2,3-Triazole Tethered Chalcone Hybrids as Potential Anticancer,” Journal Molecular Structure 1217 (2020): 1–12.
   Google Scholar
• N. Foroughifar, S. Karimi Beromi, H. Pasdar, and M. Shahi, “Synthesis of Some New Tetrahydropyrimidine Derivatives as Possible Antibacterial Agents,” Iranian Journal of Pharmaceutical Research: IJPR 16 (2017): 596–601.
   PubMed Web of Science ®Google Scholar
• T. U. Mayer, T. M. Kapoor, S. J. Haggarty, R. W. King, S. L. Schreiber, and T. J. Mitchison, “Small Molecule Inhibitor of Mitotic Spindle Bipolarity Identified in a Phenotype-Based Screen,” Science (New York, N.Y.) 286, no. 5441 (1999): 971–4.
   PubMed Web of Science ®Google Scholar
• A. Bouzina, M. Berredjem, B. Belhani, S. Bouacida, C. Marminon, M. L. Borgne, Z. Bouaziz, and M. Aissaoui, “Microwave-Accelerated Multicomponent Synthesis and X-Ray Characterization of Novel Benzothiadiazinone Dioxide Derivatives, Analogues of Monastrol,” Research on Chemical Intermediates 47, no. 4 (2021): 1359–76.
   Web of Science ®Google Scholar
• I. Leizerman, R. Avunie-Masala, M. Elkabets, A. Fich, and L. Gheber, “Differential Effects of Monastrol in Two Human Cell Lines,” Cellular and Molecular Life Sciences: CMLS 61, no. 16 (2004): 2060–70.
   PubMed Web of Science ®Google Scholar
• D. Russowsky, R. F. S. Canto, S. A. A. Sanches, M. G. M. D'Oca, A. de Fátima, R. A. Pilli, L. K. Kohn, M. A. Antônio, and J. E. de Carvalho, “Synthesis and Differential Antiproliferative Activity of Biginelli Compounds against Cancer Cell Lines: Monastrol, Oxo-Monastrol and Oxygenated Analogues,” Bioorganic Chemistry 34, no. 4 (2006): 173–82.
   PubMed Web of Science ®Google Scholar
• M. H. El‐Hamamsy, N. A. Sharafeldin, T. F. El‐Moselhy, and H. O. Tawfik, “Design, Synthesis, and Molecular Docking Study of Newmonastrol Analogues as Kinesin Spindle Protein Inhibitors,”Archiv Der Pharmazie 353, no. 8 (2020): 2000060.
   Web of Science ®Google Scholar
• A. Iraji, A. Nouri, N. Edraki, S. Pirhadi, M. Khoshneviszadeh, and M. Khoshneviszadeh, “One-Pot Synthesis of Thioxo-Tetrahydropyrimidine Derivatives as Potent β-Glucuronidase Inhibitor, Biological Evaluation, Molecular Docking and Molecular Dynamics Studies,” Bioorganic and Medicinal Chemistry 28 (2020): 1–8.
   Google Scholar
• R. Sivaramakarthikeyan, A. Karuppasamy, S. Iniyaval, K. Padmavathy, W.-M. Lim, C.-W. Mai, and C. Ramalingan, “Phenothiazine and Amide-Ornamented Novel Nitrogen Heterocyclic Hybrids: Synthesis, Biological and Molecular Docking Studies,” New Journal of Chemistry 44, no. 10 (2020): 4049–60.
   Web of Science ®Google Scholar
• V. P. de Souza, F. S. Santos, F. S. Rodembusch, C. B. Braga, C. Ornelas, R. A. Pilli, and D. Russowsky, “Hybrid 3,4-Dihydropyrimidin-2-(Thi)Ones as Dual-Functional Bioactive Molecules: Fluorescent Probes and Cytotoxic Agents to Cancer Cells,” New Journal of Chemistry 44, no. 29 (2020): 12440–51.
   Web of Science ®Google Scholar
• S. K. Ramadan, K. N. M. Halim, S. A. Rizk, and M. A. El-Hashash, “Cytotoxic Activity and Density Functional Theory Studies of Some 1,3-Diphenylpyrazolyltetrahydropyrimidine Derivatives,” Journal of the Iranian Chemical Society 17, no. 7 (2020): 1575–89.
   Web of Science ®Google Scholar
• Y. Liu, J. Liu, R. Zhang, Y. Guo, H. Wang, Q. Meng, Y. Sun, and Z. Liu, “Synthesis, Characterization, and Anticancer Activities Evaluation of Compounds Derived from 3,4-Dihydropyrimidin-2(1H)-One,” Molecules 24, no. 5 (2019): 891.
   Web of Science ®Google Scholar
• H. Atapour-Mashhad, M. Soukhtanloo, A. Massoudi, A. Shiri, and M. Bakavoli, “Synthesis and Evaluation of Cytotoxicity of 6-Amino-4-Aryl-2-Thioxo-1,2,3,4-Tetrahydropyrimidine-5-Carbonitriles,” Russian Journal of Bioorganic Chemistry 42, no. 3 (2016): 316–22.
   Web of Science ®Google Scholar
• L. Wu, X. Ma, X. Yang, and C. Zhang, “Synthesis and Biological Evaluation of b-Lapachone-Monastrol Hybrids as Potential Anticancer Agents,” European Journal of Medicinal Chemistry 203 (2020): 112594.
   PubMed Web of Science ®Google Scholar
• M. S. Malik, Z. S. Seddigi, S. Bajee, S. Azeeza, S. Riyaz, S. A. Ahmed, I. I. Althagafi, Q. M. S. Jamal, and A. Kamal, “Multicomponent Access to Novel Proline/Cyclized Cysteine Tethered Monastrol Conjugates as Potential Anticancer Agents,” Journal of Saudi Chemical Society 23, no. 4 (2019): 503–13.
   Web of Science ®Google Scholar
• N. Razzaghi-Asl, M. Kamrani-Moghadam, B. Farhangi, R. Vahabpour, R. Zabihollahi, and S. Sepehri, “Design, Synthesis and Evaluation of Cytotoxic, Antimicrobial, and anti-HIV-1 Activities of New 1,2,3,4-Tetrahydropyrimidine Derivatives,” Research in Pharmaceutical Sciences 14, no. 2 (2019): 155–66.
   PubMed Web of Science ®Google Scholar
• S. Safari, R. Ghavimi, N. Razzaghi-Asl, and S. Sepehri, “Synthesis, Biological Evaluation and Molecular Docking Study of Dihydropyrimidine Derivatives as Potential Anticancer Agents,” Journal of Heterocyclic Chemistry 57, no. 3 (2020): 1023–33.
   Web of Science ®Google Scholar
• G. D. Marconi, S. Carradori, A. Ricci, P. Guglielmi, A. Cataldi, and S. Zara, “Kinesin Eg5 Targeting Inhibitors as a New Strategy for Gastric Adenocarcinoma Treatment,” Molecules 24, no. 21 (2019): 3948.
   Web of Science ®Google Scholar
• R. Esmaeili, L. Kafi-Ahmadi, and S. Khademinia, “A Highly Efficient One-Pot Multicomponent Synthesis of 3,4-Dihydropyrimidin-2-(1H)-Ones/Thiones Catalyzed by Strontium Pyroarsenate Nano-Plates,” Journal of Molecular Structure 1216 (2020): 128124.
   Web of Science ®Google Scholar
• J. Safari and S. Gandomi-Ravandi, “Decoration of Multi-Walled Carbon Nanotubes with NiO Nanoparticles and Investigation on Their Catalytic Activity to Synthesize Pyrimidinone Heterocycles,” Journal of the Iranian Chemical Society 12, no. 1 (2015): 147–54.
   Web of Science ®Google Scholar
• N. Azizi and M. Edrisi, “Preparation of Choline Sulfate Ionic Liquid Supported on Porous Graphitic Carbon Nitride Nanosheets by Simple Surface Modification for Enhanced Catalytic Properties,” Journal of Molecular Liquids 300 (2020): 112263.
   Web of Science ®Google Scholar
• C. K. Khatri, S. M. Potadar, and G. U. Chaturbhuj, “A Reactant Promoted Solvent Free Synthesis of 3,4-Dihydropyrimidin-2(1H)-Thione Analogues Using Ammonium Thiocyanate,” Tetrahedron Letters 58, no. 18 (2017): 1778–80.
   Web of Science ®Google Scholar
• S. Moussa, A. Mehri, and B. Badraoui, “Magnesium Modified Calcium Hydroxyapatite: An Efficient and Recyclable Catalyst for the One-Pot Biginelli Condensation,” Journal of Molecular Structure 1200 (2020): 127111–7.
   Web of Science ®Google Scholar
• H. Alinezhad and K. Pakzad, “Green Synthesis of Copper Oxide Nanoparticles with an Extract of Euphorbia Maculata and Their Use in the Biginelli Reaction,” Organic Preparations and Procedures International 52, no. 4 (2020): 319–27.
   Web of Science ®Google Scholar
• K. Selvakumar, T. Shanmugaprabha, M. Kumaresan, and P. Sami, “Heteropoly Acid Supported on Activated Natural Clay-Catalyzed Synthesis of 3,4-Dihydropyrimidinones/Thiones through Biginelli Reaction under Solvent-Free Conditions,” Synthetic Communications 48, no. 2 (2018): 223–32.
   Web of Science ®Google Scholar
• Maria Damgaard, Anas Al-Khawaja, Mia Nittegaard-Nielsen, Rebekka F. Petersen, Petrine Wellendorph, and Bente Frølund, “Monastrol, a 3,4-Dihydropyrimidin-2(1H)-Thione, as Structural Scaffold for the Development of Modulators for GHB High-Affinity Binding Site Sand α1β2δ GABAA Receptors,” European Journal of Medicinal Chemistry 138 (2017): 300–12.
   PubMed Web of Science ®Google Scholar
• S. Sepehri, L. Saghaie, and A. Fassihi, “Anti-HIV‐1 Activity Prediction of Novel Gp41 Inhibitors Using Structure‐Based Virtual Screening and Molecular Dynamics Simulation,” Molecular Informatics 36, no. 3 (2017): 1600060.
   Web of Science ®Google Scholar